If I understand the implications of this article correctly a tumour may be slow to shrink or even increase in size due to the immunotherapeutic action. Hence the ORR(or even CR!)and PFS data which are so predictive of treatment success in chemotherapy do not apply to immunotherapeutics. It is MOS and long term survival that we should be looking for. AND SUCCESS IN MOS AND LONG TERM SURVIVAL ARE WHAT WE ARE GETTING WITH BAVI!
Freethemice you are Da'Man! This exactly explains why our MOS is getting better and better as time goes on...... and why we need to look at Bavi in a fully different way than standard drugs. It has been said on this board a number of times that it takes longer for immunotherapy agents to show their true affects. This is clinical evidence of that. It should give us all the more confidence in Bavi.
Can anyone give me a third mortgage so I can put some more into PPHM? .....just kidding, but that is the way I feel. :-)
News 
Market Data 
Discover 
AI
